Science_东岸01 发表评论于 2021-01-12 14:26:20
===========================================
骂人不好。
还有这是从他们的论文里来的，请学医的解释一下是不是包括无症状患者：
Confirmed Covid-19 was defined according to the Food and Drug Administration (FDA) criteria as the presence of at least one of the following symptoms: fever, new or increased cough, new or increased shortness of breath, chills, new or increased muscle pain, new loss of taste or smell, sore throat, diarrhea, or vomiting, combined with a respiratory specimen obtained during the symptomatic period or within 4 days before or after it that was positive for SARS-CoV-2 by nucleic acid amplification–based testing, either at the central laboratory or at a local testing facility (using a protocol-defined acceptable test).
Moderna 94.05% 的有效率是这样计算出来的：
Moderna had about 30000 people divided equally in two groups (vaccine and control). The vaccinated group had 11 cases of infection. The control group had 185 cases of infection.
n1 = 15000
n2 = 15000
x1 = 11
x2 = 185
The ratios are:
r1 = x1 / n1 = 0.000733
r2 = x2 / n2 = 0.012333
E = (r2 — r1) / r2 = 94.05%
辉瑞自己的95%有效率没有包括无症状的， 这是它自己的《新英格兰医学》杂志承认的（Discussion paragraph 4)
These data do not address whether vaccination prevents asymptomatic infection; a serologic end point that can detect a history of infection regardless of whether symptoms were present (SARS-CoV-2 N-binding antibody) will be reported later.
老寓公 发表评论于 2021-01-12 13:50:19
Armin 发表评论于 2021-01-12 13:30:13
按这个标准辉瑞有效率是29%，辉瑞自己的95%有效率也没包括无症状的，
*****************
真有这回事的话胡西进还不发声？ 还会轮到你发声?
巴西圣保罗州布坦坦研究所周二（12日）表示，中国科兴新冠疫苗在巴西的后期测试结果显示，该疫苗的“整体有效率”（general efficacy）为50.38%。
布坦坦研究所是科兴在巴西的合作伙伴，研究所的临床研究医学总监帕拉西奥斯（Ricardo Palacios）表示，上述结果包含了症状非常轻微或没有症状而毋须接受治疗的感染个案。布坦坦研究所上周曾公布科兴新冠疫苗对轻症的有效率为78%，指这是该疫苗的“临床有效率”（clinical efficacy），但数据被指不够全面。
购入了科兴疫苗的土耳其上月公布的中期分析数据指出，科兴疫苗有效率达91.25%：而刚在周一批准紧急使用科兴疫苗的印尼，则指中期数据显示有效率为65%。负责设计巴西临床测试的布坦坦研究所的高层说，巴西的测试参与者主要是在疫情严重爆发时期的前线医护人员，亦包括长者，因此难与其他测试的结果直接比较。